

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
COLLABORATION AGREEMENT**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

THE COLLABORATION AGREEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 13 September 2025, Zhongli (Hainan) Life Science Technology Co., Ltd.* (中驪(海南)生命科學技術有限公司) (“**Zhongli (Hainan)**”), an indirect non-wholly owned subsidiary of the Company, and Hainan Boao Super Hospital Co., Ltd.* (海南博鰲超級醫院有限公司) (“**Hainan Boao**”) signed a collaboration agreement (the “**Collaboration Agreement**”), pursuant to which, Zhongli (Hainan) and Hainan Boao jointly established the “International Precision Oncology Medical Center” (the “**Medical Center**”). Hainan Boao is responsible for providing the Center’s premises and delivering the service functions of the “1 + X” platform, including but not limited to: outpatient services, inpatient care, diagnostics, treatment, and surgical procedures. Zhongli (Hainan) is responsible for the Center’s operations while providing specialist expertise, specialized technical and equipment support. Both parties collaborate to carry out diagnostic and treatment activities as well as various scientific research projects for patients.

INFORMATION ON HAINAN BOAO

Hainan Boao is a company established in China with limited liability in 2018. Hainan Boao is the first medical institution established under the special policies of the “Nine-Point Guideline” and serves as a pioneer in China’s healthcare opening-up. It is also a hub for clinical research in advanced medical technologies and the transformation of innovative applications. Boao Super Hospital, under Hainan Boao, is positioned as a comprehensive mixed-ownership hospital with first-class facilities, disciplines, and management. It adopts a “1 + X” clustered medical service model and currently hosts 21 specially appointed academicians and expert teams. At the same time, leveraging the special policies of the “Nine-Point Guideline”, it utilizes advanced foreign drugs, medical devices and technologies to provide diagnostic and therapeutic services featuring specially imported innovative drugs and medical devices. General Secretary Xi Jinping, Premier Li Keqiang, Vice Premier Han Zheng, Vice Premier Liu Yandong and other state leaders all gave full affirmation during their inspections.

To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, as at the date of this announcement, Hainan Boao and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)).

REASONS AND BENEFITS FOR SIGNING THE COLLABORATION AGREEMENT

The Company is a company incorporated in Bermuda with limited liability and is an investment holding company. Through its subsidiaries, it is principally engaged in longevity science business, money lending, financial and investment advisory, as well as securities, property and investments. Zhongli (Hainan) is a company established in China with limited liability, primarily engaged in the provision of longevity health services in China.

The Board believes that the health and longevity science market has great prospects, as it has been observed that affluent customers around the world are more willing to accept and spend money on longevity science applications to enhance their overall health and immune status and promote their physical rejuvenation.

Signing the Collaboration Agreement is in line with the Group's longevity science business development strategy and plan and will be beneficial to the Group's future business development, laying a solid foundation for the Group's further expansion in the domestic market. The Board believes that signing the Collaboration Agreement will further improve the Group's layout in the field of longevity science diagnosis and medical services, and open up new sources of longevity science revenue for the Group, with a view to bringing more stable and sustained growth in revenue to the Group in the long run.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman and Executive Director

Hong Kong, 15 September 2025

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yan Yifan (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Lee See Barry
Mr. Huang Jiang
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Mr. Lyn Changsheng

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

* *The English translation of the name in Chinese which is marked with "*" is for identification purpose only.*